The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment

Mizutani, Kosuke; Sud, Sudha; McGregor, Natalie; Martinovski, Gari; Rice, Brandon T.; Craig, Matthew; Varsos, Zachary S.; Roca, Hernán; Pienta, Kenneth J.

doi:10.1593/neo.09988

Cited by 192 publications

(178 citation statements)

References 32 publications

Supporting

Mentioning

166

Contrasting

Order By: Relevance

“…An increase in IL-17 expression triggers the release of IL-6 inflammatory cytokines and consequently the activation of signal transducer and activator of transcription 3 (STAT3) and necrosis factor kappa β, which are associated with the production of pro-inflammatory cytokines. The tumor cells are capable of perpetuating the local inflammatory response via the expression of CCL2, which stimulates the monocyte secretory IL-17 input, contributing to inflammation and tumor growth (31,32). Additionally, STAT3 is regulated by IL-23, which promotes a protumor activity cascade and the presence of IL-23 stabilizes Th17 cells (33).…”

Section: Discussionmentioning

confidence: 99%

High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Previous studies have indicated that cancer may be promoted and/or exacerbated by inflammation and infection. The cytokines produced by activated innate immune cells that stimulate tumor growth and progression are considered as important components in this process. The interleukin (IL)-23/T helper (Th)17 axis, which exerts marked pro-inflammatory effects, has emerged as an important mediator in inflammation-associated cancer. Increasing clinical evidence indicates that Th17 may promote or inhibit tumor progression, however, the function of Th17 in the pathogenesis of benign and malignant thyroid neoplasms remains unclear. The present study investigated the association between the IL-23/Th17 axis and neoplastic and non-neoplastic thyroid lesions using immunohistochemistry. A total of 131 thyroid biopsy specimens were analyzed, which revealed high IL-17 and IL-23 expression in differentiated thyroid cancer and medullary thyroid cancer tissues when compared with benign lesions, including follicular thyroid adenoma and goiter tissues. Furthermore, high IL-17 expression was associated with recurrence and mortality. These results indicate that the IL-23/Th17 axis exhibits a pivotal function in the development of thyroid neoplasms.

show abstract

Section: Discussionmentioning

confidence: 99%

High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[42,43] Experimental studies have revealed the CCL2-dependent infiltration of macrophages into tumors. [44] For example, systemic administration of CCL2-neutralizing antibodies in tumor-bearing mice or the short-hairpin RNA knockdown of CCR2 in the cancer cell lines significantly reduced tumor growth along with reduced TAM recruitment [45] .…”

Section: Soluble Factors Mediating Macrophage Mobilization Into Tumorsmentioning

confidence: 99%

Macrophages as a Key Factor in the Process of Tumour From the Initiation to the Therapy of Cancer.

Yang¹

2017

WJPR

View full text Add to dashboard Cite

show abstract

“…The intracardiac injection was carried out according to previously published methods [36]. Briefly, six-week-old NOD/ SCID mice were anesthetized with isoflurane gas (a 2% isofluorane/air mixture) and injected in the left ventricle of the heart with 100,000 cells in 100 ml of sterile Dulbecco's PBS lacking Ca 2+ and Mg 2+ .…”

Section: Intra-cardiac Injectionmentioning

confidence: 99%

RNAi as a Routine Route Toward Breast Cancer Therapy

Hannon¹

2014

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE (DD-MM-YYYY)May 2014 (From -To) 1Sep2008-28Feb2014 REPORT TYPE Final DATES COVERED TITLE AND SUBTITLERNAi as a Routine Route Toward Breast Cancer Therapy 5a. CONTRACT NUMBER 5b. GRANT NUMBER W81XWH-08-1-0572 5c. PROGRAM ELEMENT NUMBER AUTHOR(S)Gregory J. Hannon, PhD. 5d. PROJECT NUMBERemail: hannon@cshl.edu 5e. TASK NUMBER 5f. WORK UNIT NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERCold Spring Harbor Laboratory One Bungtown Road Cold Spring Harbor, NY 11724 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)US Army Medical Research and Materiel Command Fort Detrick, MA 21702 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited SUPPLEMENTARY NOTES ABSTRACTDuring the first year of this innovator award, we made significant progress toward two of our aims. We constructed a third generation RNAi library and made that available to the breast cancer community. This resource has nearly 75,000 independent, sequence verified clones targeting ~18,000 human genes. A similar library for the mouse genome is nearing completion. We also scaled up our shRNA screening platform in preparation for lethality surveys of all suitable and available BC cell lines, including matched pairs of lines that have acquired resistance to herceptin in vitro. Relevant to our second aim, we have profiled microRNA from each of the identifiable epithelial cell types in the mouse mammary gland and are undertaking similar efforts in human. The goal is to develop microRNA sensor strategies that will permit visualization of each cell type in vivo and enable their isolation and manipulation in vitro. Finally, we showed that two microRNAs, let-7 and miR-93, can deplete tumor initiating cells from a number of basal breast cancer cell lines. SUBJECT TERMS INTRODUCTIONThe goal of this innovator award is to continue to develop and apply RNAi-based screening methods to discover new routes toward breast cancer therapy. The project has three sets of goals. First is to integrate genomic and geneti...

show abstract

The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment

Cited by 192 publications

References 32 publications

High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer

High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer

Macrophages as a Key Factor in the Process of Tumour From the Initiation to the Therapy of Cancer.

RNAi as a Routine Route Toward Breast Cancer Therapy

Contact Info

Product

Resources

About